US warns of drugs in Reumofan dietary supplements

(AP) — The U.S. Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among Americans taking the Mexico-manufactured pills.

Reumofan Plus and Reumofan Plus Premium are marketed as natural remedies for arthritis and muscle pain, but the FDA says the actually contain several prescription drugs.

A chemical analysis by the agency found that Reumofan Plus contains three drugs, including the muscle relaxant methocarbomal and the anti-inflammatory dexamethasone. These drugs can interact with other medications, causing life-threatening side effects in some patients.

The FDA first warned consumers about the products in June, but says complications have continued to be reported.

Reumofan products are manufactured in Mexico by Riger Naturals and sold in the U.S. at retail shops and over the Internet.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA seizes sexual enhancement products

Apr 10, 2008

The U.S. Food and Drug Administration announced the seizure by U.S. marshals of more than 14,000 units of Shangai- and Naturale-brand diet supplements.

FDA cracks down on illegal supplements

Dec 15, 2010

(AP) -- The Food and Drug Administration is cracking down on manufacturers of certain weight loss, body building and sexual enhancement supplements that contain potentially dangerous ingredients.

Recommended for you

New system targets germs in donated blood plasma

22 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.